Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800
Inovio Pharmaceuticals, Inc. (INO)
NASDAQ:AMEX Investor Relations:
ir.inovio.com/investors/default.aspx
Company Research
Source: PR Newswire
PLYMOUTH MEETING, Pa., March 3, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced an accelerated timeline for developing its DNA vaccine INO-4800 to address COVID-19, the respiratory infection the World Health Organization (WHO) has designated a Public Health Emergency of International Concern of the highest level. According to WHO, approximately 89,000 cases have been reported globally with more than 3,000 deaths.Dr. J. Joseph Kim, Inovio's President & CEO, shared this accelerated timeline at the U.S. Coronavirus Task Force meeting at the White House on March 2. Dr. Kim said, "Inovio is the leader in coronavirus vaccine development and the only company with a Phase 2 vaccine for a related coronavirus that causes Middle East Respiratory Syndrome (MERS). Using our modern DNA medicines platform, we designed our DNA vaccine INO-4800 in three hours after the publication of the genetic sequence of the novel coronavirus that causes COVID-19."Dr. Kim continued, "
Show less
Read more
Impact Snapshot
Event Time:
INO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INO alerts
High impacting Inovio Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
INO
News
- Human Papillomavirus Market is Projected to Boost at a Moderate Growth Rate During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) had its price target lowered by analysts at HC Wainwright from $12.00 to $5.00. They now have a "neutral" rating on the stock.MarketBeat
- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $33.00 to $15.00. They now have an "outperform" rating on the stock.MarketBeat
- Inovio Pharmaceuticals Third Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) had its price target lowered by analysts at Royal Bank of Canada from $7.00 to $6.00. They now have a "sector perform" rating on the stock.MarketBeat
INO
Earnings
- 11/14/24 - Beat
INO
Sec Filings
- 11/14/24 - Form 8-K
- 11/14/24 - Form 10-Q
- 11/8/24 - Form SC
- INO's page on the SEC website